Evidence Hub

Successful Treatment of Steroid‐Dependent Severe Eosinophilic Pneumonia With Benralizumab: A Case Report

Takeru Ichikawa, Yukiko Takigawa, K. Fujiwara, Tomoyoshi Inoue, Shoichiro Matsumoto, Keisuke Shiraha, Mayu Goda, S. Matsuoka et al.

Respirology Case Reports, 2025

Abstract

Eosinophilic pneumonia (EP) often requires long‐term steroid treatment, which has adverse effects. We report the case of an 83‐year‐old male with minimal‐change nephrotic syndrome, refractory asthma and steroid‐induced diabetes who developed a severe steroid‐dependent EP relapse during steroid tapering. Considering his age, comorbidities and steroid dependency, treatment with benralizumab, an anti‐interleukin‐5 receptor antibody, was initiated. Benralizumab rapidly depleted eosinophils, leading to significant clinical and radiological improvements, allowing successful sustained tapering of prednisolone to 5 mg daily, and improving diabetes control without EP relapse. Benralizumab provides effective steroid‐sparing therapy for steroid‐dependent EP, particularly in complex patients.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free